Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 3
1994 3
1995 11
1996 1
1997 8
1998 5
1999 11
2000 13
2001 32
2002 20
2003 31
2004 25
2005 46
2006 42
2007 50
2008 52
2009 62
2010 63
2011 69
2012 77
2013 86
2014 108
2015 120
2016 119
2017 140
2018 121
2019 141
2020 160
2021 160
2022 159
2023 191
2024 94

Text availability

Article attribute

Article type

Publication date

Search Results

1,933 results

Results by year

Filters applied: . Clear all
Page 1
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, Scagliarini S, Crocetto F, Bianco R, Formisano L. Ascione CM, et al. Cancer Treat Rev. 2023 Apr;115:102530. doi: 10.1016/j.ctrv.2023.102530. Epub 2023 Feb 28. Cancer Treat Rev. 2023. PMID: 36898352 Free article. Review.
FGFR3 gene rearrangements are typical alterations in bladder cancer (Nelson et al., 2016; Parker et al., 2014). In this review, we summarize the most relevant evidence on the role of FGFR3 and the state-of-art of anti-FGFR3 treatment in bladder canc …
FGFR3 gene rearrangements are typical alterations in bladder cancer (Nelson et al., 2016; Parker et al., 2014). In this review …
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, Li W, Han B, Chen S, Shi B. Jing W, et al. Cancer Res. 2022 Jan 1;82(1):114-129. doi: 10.1158/0008-5472.CAN-21-2362. Epub 2021 Nov 9. Cancer Res. 2022. PMID: 34753771
However, the role and detailed molecular mechanism of FGFR3 in the immune microenvironment of bladder cancer remain largely unknown. Here, we demonstrate that inhibition of FGFR3 in FGFR3-activated bladder cancer elevates PD-L1 protein levels by …
However, the role and detailed molecular mechanism of FGFR3 in the immune microenvironment of bladder cancer remain largely un …
FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.
Ouyang Y, Ou Z, Zhong W, Yang J, Fu S, Ouyang N, Chen J, Xu L, Wu D, Qian J, Lin Y, Lin T, Huang J. Ouyang Y, et al. Cancer Res. 2023 Dec 15;83(24):4030-4046. doi: 10.1158/0008-5472.CAN-23-1065. Cancer Res. 2023. PMID: 37768887 Free PMC article.
FGFR3 alterations are common in patients with bladder cancer. While the FGFR tyrosine kinase inhibitor erdafitinib has been approved as a targeted therapy for patients with FGFR3-altered (aFGFR3) bladder cancer, the response rate remains suboptimal, pr …
FGFR3 alterations are common in patients with bladder cancer. While the FGFR tyrosine kinase inhibitor erdafitinib has been ap …
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H. Katoh M, et al. Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21. Med Res Rev. 2014. PMID: 23696246 Review.
FGF signaling to PI3K-AKT branch and Hedgehog, Notch, TGFbeta, and noncanonical WNT signaling cascades regulate epithelial-to-mesenchymal transition (EMT) and invasion. Gene amplification of FGFR1 occurs in lung cancer and estrogen receptor (ER)-positive breast cancer …
FGF signaling to PI3K-AKT branch and Hedgehog, Notch, TGFbeta, and noncanonical WNT signaling cascades regulate epithelial-to-mesenchymal tr …
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.
Kacew A, Sweis RF. Kacew A, et al. Front Immunol. 2020 Nov 5;11:575258. doi: 10.3389/fimmu.2020.575258. eCollection 2020. Front Immunol. 2020. PMID: 33224141 Free PMC article. Review.
FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of FGFR3 in bladder cancer …
FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as …
Anticancer drug resistance: An update and perspective.
Nussinov R, Tsai CJ, Jang H. Nussinov R, et al. Drug Resist Updat. 2021 Dec;59:100796. doi: 10.1016/j.drup.2021.100796. Epub 2021 Dec 16. Drug Resist Updat. 2021. PMID: 34953682 Free PMC article. Review.
For example, the common KRas(G12C) driver mutation emerges in different cancers. Most occur in NSCLC, but some occur, albeit to a lower extent, in colorectal cancer and pancreatic ductal carcinoma. The responses to KRas(G12C) inhibitors are variable and fall into th …
For example, the common KRas(G12C) driver mutation emerges in different cancers. Most occur in NSCLC, but some occur, albeit to a low …
[FGFR3 overexpression is a relevant alteration in colorectal cancer].
Fromme JE, Schildhaus HU. Fromme JE, et al. Pathologe. 2018 Dec;39(Suppl 2):189-192. doi: 10.1007/s00292-018-0504-0. Pathologe. 2018. PMID: 30267148 Review. German.
CONCLUSIONS: FGFR3 overexpression defines a subgroup of metastatic colorectal cancers with an unfavourable prognosis. Since FGFR3 alterations can present a potential therapeutic target, patients with FGFR3 overexpression should be included into clinica …
CONCLUSIONS: FGFR3 overexpression defines a subgroup of metastatic colorectal cancers with an unfavourable prognosis. Since …
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. Helsten T, et al. Clin Cancer Res. 2016 Jan 1;22(1):259-67. doi: 10.1158/1078-0432.CCR-14-3212. Epub 2015 Sep 15. Clin Cancer Res. 2016. PMID: 26373574
FGFR1 (mostly amplification) was affected in 3.5% of 4,853 patients; FGFR2 in 1.5%; FGFR3 in 2.0%; and FGFR4 in 0.5%. Almost every type of malignancy examined showed some patients with FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGF …
FGFR1 (mostly amplification) was affected in 3.5% of 4,853 patients; FGFR2 in 1.5%; FGFR3 in 2.0%; and FGFR4 in 0.5%. Almost every ty …
FGFR3 signaling and function in triple negative breast cancer.
Chew NJ, Nguyen EV, Su SP, Novy K, Chan HC, Nguyen LK, Luu J, Simpson KJ, Lee RS, Daly RJ. Chew NJ, et al. Cell Commun Signal. 2020 Jan 27;18(1):13. doi: 10.1186/s12964-019-0486-4. Cell Commun Signal. 2020. PMID: 31987043 Free PMC article.
BACKGROUND: Triple negative breast cancer (TNBC) accounts for 16% of breast cancers and represents an aggressive subtype that lacks targeted therapeutic options. ...The selective FGFR1-3 inhibitor, PD173074 and siRNA knockdowns were used to characterize the function …
BACKGROUND: Triple negative breast cancer (TNBC) accounts for 16% of breast cancers and represents an aggressive subtype that …
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. Krook MA, et al. Br J Cancer. 2021 Mar;124(5):880-892. doi: 10.1038/s41416-020-01157-0. Epub 2020 Dec 3. Br J Cancer. 2021. PMID: 33268819 Free PMC article. Review.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5-10% of all human cancers, although this frequency increases to 10-30% in urothelial carcinoma and intrahepatic cholangio …
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifi …
1,933 results